The focus of this proposal is to develop a new class of potent and selective small molecule inhibitors of a genetically validated cancer target for further therapeutic development by enhancing the potency of our initial hit. Our inhibitors will occupy a unique niche in the landscape of small molecule precision therapeutics in cancer.
Funding
Funding Duration
July 1, 2018 - June 30, 2020
Funding level
Development
People
Principal Investigator
Stephen Blacklow
MD, PhD
Gustavus Adolphus Pfeiffer Professor of Biological Chemistry and Molecular Pharmacology, Harvard Medical School
Co-PI
Jonathan LaRochelle
PhD
Scientist at Relay Therapeutics
Vidyasiri Vemulapalli
PhD
Research Fellow in Biological Chemistry and Molecular Pharmacology (EXT), Dana-Farber Cancer Institute